TrialAnnals of oncology : official journal of the European Society for Medical Oncology2014

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.

H S Rugo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.